|
Discontinuation. |
||||
| Discontinued |
||||
|
|
||||
| Reason and statin |
Number of trials |
Duration (wks) |
Number |
Percent |
|
|
||||
| Discontinuation for any reason |
||||
| Atorvastatin |
3 |
16/52 |
59/1066 |
6 |
| Cerivastatin |
4 |
24–32 |
27/754 |
4 |
| Fluvastatin |
6 |
12–24 |
54/518 |
10 |
| Lovastatin |
5 |
12/18 wks |
64/879 |
7 |
| Pravastatin |
17 |
12 wks – 5 yrs |
707/5831 |
12 |
| Rosuvastatin |
1 |
12 |
15/235 |
6 |
| Simvastatin |
13 |
12 wks – 5.4 yrs |
1605/13898 |
12 |
| Placebo |
16 |
13 wks – 5.4 yrs |
2692/17314 |
16 |
|
|
||||
| Discontinuation because of adverse events |
||||
| Atorvastatin |
1 |
52 |
7/227 |
3 |
| Cerivastatin |
2 |
24–32 |
27/754 |
4 |
| Fluvastatin |
7 |
12–24 |
43/860 |
5 |
| Lovastatin |
9 |
12 wks – 2 yrs |
26/1180 |
2 |
| Pravastatin |
28 |
12 wks – 5 yrs |
136/5403 |
3 |
| Rosuvastatin |
1 |
12 |
8/235 |
3 |
| Simvastatin |
17 |
12 wks – 5.4 yrs |
199/5133 |
4 |
| Placebo |
24 |
13 wks – 5.4 yrs |
280/6072 |
5 |
Edwards and Moore BMC Family Practice 2003 4:18 doi:10.1186/1471-2296-4-18 |
||||